SCHEMBL20950693

SCHEMBL20950693

CC(C)CN1CCC(F)(C(=O)Nc2cc3cc(-n4nccn4)ccc3nn2)CC1

nearest known ligand 0.76

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 19/20 0.76
GSK3B P49841 17/20 0.58
WNT1 P04628 9/20 0.50
ALDH1A1 P00352 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
DYRK3 O43781 1/20 0.35
CLK1 P49759 1/20 0.35
CLK2 P49760 1/20 0.35
CLK3 P49761 1/20 0.35
CDK5 Q00535 1/20 0.35
CDK5R1 Q15078 1/20 0.35
DYRK2 Q92630 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
DYRK4 Q9NR20 1/20 0.35
DYRK1B Q9Y463 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20949913 0.87 DYRK1A (0.77) DYRK1AGSK3BWNT1ALDH1A1CYP3A4
SCHEMBL19515378 0.86 DYRK1A (1.00) DYRK1AGSK3BWNT1DYRK3CLK1
SCHEMBL30005133 0.86 DYRK1A (1.00) DYRK1AGSK3BWNT1DYRK3CLK1
SCHEMBL20946633 0.84 DYRK1A (0.77) DYRK1AGSK3BWNT1DYRK3CLK1
SCHEMBL20947896 0.81 DYRK1A (0.78) DYRK1AGSK3BWNT1DYRK3CLK1
SCHEMBL20951115 0.80 DYRK1A (0.79) DYRK1AGSK3BWNT1CLK2CLK3
SCHEMBL20951198 0.79 DYRK1A (0.75) DYRK1AGSK3BWNT1DYRK3CLK1
SCHEMBL20950305 0.79 DYRK1A (0.79) DYRK1AGSK3BWNT1
SCHEMBL20950884 0.79 DYRK1A (0.79) DYRK1AGSK3BWNT1CLK2CLK3
SCHEMBL20947004 0.77 DYRK1A (0.77) DYRK1AGSK3BWNT1DYRK3CLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10703748-B2 Diazanaphthalen-3-yl carboxamides and preparation and use thereof SAMUMED, LLC (US) 2020-07-07 US claimed
US-20190127370-A1 DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2019-05-02 US claimed
US-10703748-B2 Diazanaphthalen-3-yl carboxamides and preparation and use thereof SAMUMED, LLC (US) 2020-07-07 US disclosed
US-20190127370-A1 DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127370-A1 DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF DYRK1A, DKK1, WNT1 DYRK1A 1/4885GSK3B 19/4885WNT1 3/4885
US-10703748-B2 Diazanaphthalen-3-yl carboxamides and preparation and use thereof DYRK1A, DKK1, WNT1 DYRK1A 1/4885GSK3B 19/4885WNT1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.